Peptide Information
General Information of This Peptide
| Peptide ID |
PEP00053
|
|||||
|---|---|---|---|---|---|---|
| Peptide Name |
Transportan
|
|||||
| Structure |
|
|||||
| Sequence |
GWTLNSAGYLLGKINLKALAALAKKIL
|
|||||
| Peptide Type |
Linear
|
|||||
| PDC Transmembrane Types | Cell-penetrating peptides (CPPs) | |||||
| Distribution |
The distribution of the 111In-labeled CPPs after i.v. injection in PC-3 tumor-bearing mice is shown in Tables 3 5 as the percentage of the injected dose per gram tissue (%ID/g). All of the radiolabeled CPPs showed a relatively fast blood clearance with %ID/g values decreasing to less than 1 %ID/g after 4 h. In general, the tumor showed the lowest uptake rates among all organs (except for the brain and muscles) for all of the peptides studied. Noticeable values were observed for R9 with 51.4 %ID/g in the liver 10 min after injection, and a rapid accumulation of 81.4 %ID/g in the kidneys was observed for NLS just after 10 min. Penetratin was found to cross the blood brain barrier within 10 min at a level of 0.9 %ID/g in the brain indicating a distinct blood brain barrier permeability of CPPs. After 4 h, all of the peptides (except for PreS2-TLM) were retained in the liver and the kidneys. A high spleen uptake was observed after 4 h for both penetratin and R9 (7.1 %ID/g and 9.1 %ID/g, respectively).
|
|||||
| Formula |
C134H226N34O33
|
|||||
| Isosmiles |
[H]NCCCC[C@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O[H])cc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO[H])NC(=O)[C@H](CC(=O)N[H])NC(=O)[C@H](CC(C)C)NC(=O)[C@@]([H])(NC(=O)[C@H](Cc1cn([H])c2ccccc12)NC(=O)CN[H])[C@@H](C)O[H])C(=O)N[C@]([H])(C(=O)N[C@@H](CC(=O)N[H])C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN[H])C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN[H])C(=O)N[C@@H](CCCCN[H])C(=O)N[C@]([H])(C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)CC)[C@@H](C)CC
|
|||||
| InChI |
InChI=1S/C134H226N34O33/c1-25-74(17)108(131(197)163-100(61-104(141)173)127(193)160-94(54-70(9)10)123(189)155-88(40-30-34-48-136)117(183)147-80(23)115(181)157-92(52-68(5)6)121(187)148-77(20)112(178)145-78(21)114(180)156-93(53-69(7)8)122(188)149-79(22)113(179)153-89(41-31-35-49-137)118(184)154-90(42-32-36-50-138)120(186)167-109(75(18)26-2)132(198)164-101(134(200)201)57-73(15)16)166-119(185)87(39-29-33-47-135)150-106(175)65-144-116(182)91(51-67(3)4)158-124(190)95(55-71(11)12)159-126(192)97(58-82-43-45-84(171)46-44-82)152-107(176)64-143-111(177)76(19)146-130(196)102(66-169)165-128(194)99(60-103(140)172)161-125(191)96(56-72(13)14)162-133(199)110(81(24)170)168-129(195)98(151-105(174)62-139)59-83-63-142-86-38-28-27-37-85(83)86/h27-28,37-38,43-46,63,67-81,87-102,108-110,142,169-171H,25-26,29-36,39-42,47-62,64-66,135-139H2,1-24H3,(H2,140,172)(H2,141,173)(H,143,177)(H,144,182)(H,145,178)(H,146,196)(H,147,183)(H,148,187)(H,149,188)(H,150,175)(H,151,174)(H,152,176)(H,153,179)(H,154,184)(H,155,189)(H,156,180)(H,157,181)(H,158,190)(H,159,192)(H,160,193)(H,161,191)(H,162,199)(H,163,197)(H,164,198)(H,165,194)(H,166,185)(H,167,186)(H,168,195)(H,200,201)/t74-,75-,76-,77-,78-,79-,80-,81+,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,108-,109-,110-/m0/s1
|
|||||
| InChIKey |
NCOFRWTVDUAEHE-CWUSWOHSSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
2841.487
|
Polar area
|
1086.66
|
||
|
Complexity
|
2839.705156
|
xlogp Value
|
-6.2761
|
|||
|
Heavy Count
|
201
|
Rot Bonds
|
105
|
|||
|
Hbond acc
|
37
|
Hbond Donor
|
38
|
|||
Each Peptide-drug Conjugate Related to This Peptide
Full Information of The Activity Data of The PDC(s) Related to This Peptide
Cq-C4-Transportan [Investigative]
Obtained from the Model Organism Data
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Malaria | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
5.2 µM
|
|||
| MOA of PDC |
The significant increase in the hemolytic activity of TP10 upon conjugation to the 4-aminoquinoline suggests that drug cargo prevents an otherwise active CPP carrier from exerting the desired cell penetrating/antiplasmodial action safely, as it produces conjugates that exert membranolytic activity.
|
||||
| Description |
Only three of the Cq-C4-CPP conjugates, namely, 5a, 5b, and 5g, displayed IC50 values below 10 μM, with TP10- and Transportan-derived conjugates 5a (IC50 = 1.52 μM) and 5b (IC50 = 5.20 μM) being the most active.
|
||||
| In Vivo Model | Plasmodium falciparum W2. | ||||
References